The US Food and Drug Administration (HKG:9926) approved Akeso's penpulimab-kcqx combination with cisplatin or carboplatin and gemcitabine for the treatment of nasopharyngeal carcinoma.
The drug, a differentiated PD-1 monoclonal antibody, is indicated for the treatment of recurrent or metastatic non-keratinizing nasopharyngeal carcinoma in adults, according to a Friday filing with the Hong Kong bourse.
Chinese authorities have already approved the drug for first-line treatment of advanced nasopharyngeal carcinoma and second or later-line treatment of advanced nasopharyngeal carcinoma, the filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。